Home > Oncology > ASCO 2022 > Autologous stem cell transplantation plus RVd improves PFS in newly diagnosed multiple myeloma

Autologous stem cell transplantation plus RVd improves PFS in newly diagnosed multiple myeloma

Presented By
Prof. Paul Richardson, Harvard Medical School, MA, USA
Conference
ASCO 2022
Trial
Phase 3, DETERMINATION
Lenalidomide-bortezomib-dexamethasone (RVd) plus autologous stem cell transplantation (ASCT) delivered superior progression-free survival (PFS) to patients with newly diagnosed multiple myeloma compared with dexamethasone alone in the phase 3 DETERMINATION trial. However, no difference in overall survival (OS) was observed between the 2 regimens after 6 years of follow-up. The phase 3 DETERMINATION trial (NCT01208662) randomised patients with newly diagnosed multiple myeloma to RVd alone (n=357) or RVd plus ASCT (n=365). After the induction phase, ASCT, and consolidation therapy, all patients received lenalidomide maintenance therapy. The primary outcome measure was PFS. Notably, approximately 20% of the included patients was African American. Prof. Paul Richardson (Harvard Medical School, MA, USA) presented the results [1]. The median PFS was significantly ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on